Twitter Beğeni Hilesi

Here are the top health care issues Democrats will likely highlight at the DNC. trib.al/AYqx3cN

Lilly’s Zepbound slashed risk of developing diabetes statnews.com/2024/08/20/zep… via STAT

ICYMI: Private biotech investors may be warming to the AI drug dev field. But, the public markets are still uncertain. Companies like Recursion are burning through cash, leading some to think the Exscientia merger was about money, not boosting R&D. statnews.com/2024/08/19/rec… $RXRX

A House committee is investigating whether brand drug companies are collaborating with the Chinese military when they run clinical trials in that country, John Wilkerson writes. statnews.com/2024/08/20/bio…

Nobody will remember: - your salary - how "busy you were" - how many hours you worked people will remember: - the 2024 #STATSummit (and the suit Nicholas St. Fleur wears) Register here: statnews.com/2024/summit/20…

Academia and the biotech industry's relationship is shifting, gene therapy researchers say. “I think academia will have to find a new spot in this success story that it created.”

Tome Biosciences, once a high-flying gene-editing startup, is floundering statnews.com/2024/08/22/tom… via Jason Mast Allison DeAngelis

#DNC2024CHICAGO #DNC2024

In a layoff notice filed Friday in Massachusetts, the gene-editing startup said it would lay off nearly its entire staff of 130 employees. trib.al/IQFBuw9

In which Helen Branswell 🇨🇦 talks to Anthony Fauci about his West Nile experience. “I have to tell you, I’ve never been as sick in my life. Ever." statnews.com/2024/08/24/fau…

Smart story from Elaine Chen: Eli Lilly’s lauded discount of its obesity drug Zepbound comes with caveats. statnews.com/2024/08/28/eli…

Geesh, I missed the second $DYN announcement this morning: The CMO, COO and CBO (chief business officer )are also leaving. investors.dyne-tx.com/news-releases/…

Just in: Recursion Pharmaceuticals releases topline data on its lead drug for cerebral cavernous malformations. While a success on paper, the data likely won’t satisfy many investors closely watching the AI drug developer. statnews.com/2024/09/03/rec… $RXRX

For background on Recursion and its drug development plans, check out my feature from last month —statnews.com/2024/08/19/rec… $RXRX

Exclusive: Novartis is opening a new manufacturing facility in California and expanding an existing production site in its bid to dominate the booming radiopharmaceuticals field amid burgeoning competition. statnews.com/2024/09/04/nov… $NVS

I'm really thrilled with all the reaction to this story from long-time industry executives, regulators, and patients. We're taking an unusual step at STAT -- we're putting it in front of the paywall. So if you didn't get to read it yet, now's your chance.

Companies look to the amylin hormone as the next big obesity target that could rival GLP-1, arguing that amylin drugs could cause less nausea and muscle loss. w/ Allison DeAngelis statnews.com/2024/09/05/obe…

Today, every living former CDC director since 1977 writes in STAT warning against proposals to hollow out the agency: "The CDC needs to be strengthened, not hamstrung." statnews.com/2024/09/05/cdc…

Summit Therapeutics $SMMT vs. Merck $MRK: Prepping for a big lung cancer study reveal statnews.com/2024/09/05/sum… A look ahead at the HARMONi-2 study presentation on Sunday at #WCLC24

On Sunday, we'll finally get a look at the buzzy data from a head-to-head Phase 3 trial of Summit Therapeutics' drug vs Keytruda. Adam Feuerstein ✡️'s got the rundown: statnews.com/2024/09/05/sum… $SMMT